FDA has reversed its stance that certain comparative clinical studies, including switching studies, are needed to prove interchangeability for insulin products, in a move that could speed access to less expensive insulin products. In a draft guide published Monday (Nov. 25), FDA says it has decided, based on decades of experience with insulin, that certain studies may in fact not be needed. Former FDA chief Scott Gottlieb said the move provides a more efficient pathway for interchangeable insulin products, and...